retatrutide triple hormone receptor agonist metabolic A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Unapproved weight loss drug retatrutide
Description
58 kg weight loss
suggested GLP-1 as a main component of gluco-regulation after BS [42]
Our telehealth weight loss program offers a personalized, science-based approach to help you reach and maintain your ideal weight from the comfort of your own home
The downside is that the population may not be representative of the overall population since it is made of veterans (for example, 95% male)
Yamaoka-Tojo M, Tojo T, Takahira N, Matsunaga A, Aoyama N, et al
GLP-1 medications carry serious risks, including risks of thyroid C-cell tumors (which includes thyroid cancer) and medullary thyroid carcinoma (MTC)
